NEW YORK, Aug. 2, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed’s management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, to be held in Boston, MA, August 8-11…


Previous articleCanadian Patent Grant Strengthens Small Pharma’s International Position
Next articleCOMPASS Pathways plc announces second quarter 2022 financial results and business highlights